Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship

Clinical Infectious Diseases

Volumn 44, Issue 2, 2007, Pages 159-177

  Dellit, Timothy H ^a   Owens, Robert C ^b   McGowan Jr , John E ^c   Gerding, Dale N ^d   Weinstein, Robert A ^e   Burke, John P ^f   Huskins, W Charles ^g   Paterson, David L ^h   Fishman, Neil O ⁱ   Carpenter, Christopher F ^j   Brennan, P J ⁱ   Billeter, Marianne ^k   Hooton, Thomas M ^l,m  

^a UNIVERSITY OF WASHINGTON   (United States)

^b MAINE MEDICAL CENTER   (United States)

^c EMORY UNIVERSITY   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f UNIVERSITY OF UTAH   (United States)

^g Mayo Clinic   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ UNIVERSITY OF PENNSYLVANIA   (United States)

^j WILLIAM BEAUMONT HOSPITAL   (United States)

^k OCHSNER CLINIC FOUNDATION   (United States)

^l UNIVERSITY OF MIAMI   (United States)

^m UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE AMPC; CEFOTAXIME; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; EXTENDED SPECTRUM BETA LACTAMASE; FLUCONAZOLE; GENTAMICIN; LINEZOLID; METRONIDAZOLE; OXAZOLIDINONE DERIVATIVE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN; TOBRAMYCIN; VANCOMYCIN; VORICONAZOLE;

ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COST BENEFIT ANALYSIS; COST CONTROL; DRUG CHOICE; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; EVALUATION; EVIDENCE BASED MEDICINE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HEALTH CARE QUALITY; HEALTH PROGRAM; HOSPITALIZATION; HUMAN; INFECTION; LENGTH OF STAY; MEDICAL AUDIT; MEDICAL EDUCATION; MEDICAL PRACTICE; MEDICAL SOCIETY; MINIMUM INHIBITORY CONCENTRATION; MONEY; MONOTHERAPY; NONHUMAN; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; TEAMWORK; UNITED STATES;

ANTI-BACTERIAL AGENTS; DECISION SUPPORT TECHNIQUES; DRUG ADMINISTRATION ROUTES; DRUG UTILIZATION; FORMULARIES, HOSPITAL; HOSPITALS; PHARMACY SERVICE, HOSPITAL; PRACTICE GUIDELINES; SOCIETIES, MEDICAL; SOFTWARE; UNITED STATES;

EID: 33846153776     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/510393     Document Type: Review

References (173)

1. Kish, MA. Guide to development of practice guidelines. Clin Infect Dis 2001; 32:851-4.
2. Schentag JJ, Ballow CH, Fritz AL, et al. Changes in antimicrobial agent usage resulting from interactions among clinical pharmacy, the infectious disease division, and the microbiology laboratory. Diagn Microbiol Infect Dis 1993; 16:255-64.
3. Carling P, Fung T, Killion A, Terrin N, Barza M. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol 2003; 24:699-706.
4. LaRocco A Jr. Concurrent antibiotic review programs-a role for infectious diseases specialists at small community hospitals. Clin Infect Dis 2003; 37:742-3.
5. Ansari F, Gray K, Nathwani D, et al. Outcomes of an intervention to improve hospital antibiotic prescribing: interrupted time series with segmented regression analysis. J Antimicrob Chemother 2003; 52: 842-8.
6. Ruttimann S, Keck B, Harmeier C, Maetzel A, Bucher HC. Long-term antibiotic cost savings from a comprehensive intervention program in a medical department of a university-affiliated teaching hospital. Clin Infect Dis 2004; 38:348-56.
7. Lutters M, Harbarth S, Janssens J-P, et al. Effect of a comprehensive, multidisciplinary, educational program on the use of antibiotics in a geriatric university hospital. J Am Geriatr Soc 2004; 52:112-6.
8. Scheckler WE, Bennett JV. Antibiotic usage in seven community hospitals. JAMA 1970; 213:264-7.
9. Marr JJ, Moffet HL, Kunin CM. Guidelines for improving the use of antimicrobial agents in hospitals: a statement by the Infectious Diseases Society of America. J Infect Dis 1988; 157:869-76.
10. Shlaes DM, Gerding DN, John JF, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America joint committee on the prevention of antimicrobial resistance: guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25:584-99.
11. Lawton RM, Fridkin SK, Gaynes RP, McGowan JE. Practices to improve antimicrobial use at 47 US hospitals: the status of the 1997 SHEA/IDSA position paper recommendations. Infect Control Hosp Epidemiol 2000; 21:256-9.
12. Girouard S, Levine G, Goodrich K, et al. Infection control programs at children's hospitals: a description of structures and processes. Am J Infect Control 2001; 29:145-51.
13. Sunenshine RH, Liedtke LA, Jernigan DB, Strausbaugh LJ. Role of infectious disease consultants in management of antimicrobial use in hospitals. Clin Infect Dis 2004; 38:934-8.
14. Burke JP. Infection control: a problem for patient safety. N Engl J Med 2003; 348:651-6.
15. John JF, Fishman NO. Programmatic role of the infectious diseases physician in controlling antimicrobial costs in the hospital. Clin Infect Dis 1997; 24:471-85.
16. Reimann HA. The misuse of antimicrobics. Med Clin North Am 1961; 45:849-56.
17. Kislak JW, Eickhoff TC, Finland M. Hospital-acquired infections and antibiotic usage in the Boston City Hospital-January, 1964. N Engl J Med 1964; 271:834-5.
18. Roberts AW, Visconti JA. The rational and irrational use of systemic antimicrobial drugs. Am J Hosp Pharm 1972; 29:828-34.
19. McGowan JE. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983; 5:1033-48.
20. Monroe S, Polk R. Antimicrobial use and bacterial resistance. Curr Opin Microbiol 2000; 3:496-501.
21. Barbosa TM, Levy SB. The impact of antibiotic use on resistance development and persistence. Drug Resistance Updates 2000; 3: 303-11.
22. Paterson DL. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin Infect Dis 2004; 38(Suppl 4):S341-5.
23. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989; 23:441-51.
24. Chow JW, Fine MJ, Shlaes DM, et al. Enterobacter bacteremia: clinical features and emergence of antibiotic resistance during therapy. Ann Intern Med 1991; 115:585-90.
25. Conus P, Francioli P. Relationship between ceftriaxone use and resistance of Enterobacter species. J Clin Pharm Ther 1992; 17:303-5.
26. Seppala H, Klaukka T, Vuopio-Varkila J, et al. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl J Med 1997; 337: 441-6.
27. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA 1998; 280:1233-7.
28. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units. JAMA 2003; 289:885-8.
29. Muller AA, Mauny F, Bertin M, et al. Relationship between spread of methicillin-resistant Staphylococcus aureus and antimicrobial use in a French university hospital. Clin Infect Dis 2003; 36:971-8.
30. Polk RE, Johnson CK, McClish D, Wenzel RP, Edmond MB. Predicting hospital rates of fluoroquinolone-resistant Pseudomonas aeruginosa from fluoroquinolone use in US hospitals and their surrounding communities. Clin Infect Dis 2004; 39:497-503.
31. Paterson DL, Wen-Chien K, Von Gottberg A, et al. International prospective study of Klebsiella pneumoniae bacteremia: implications of extended-spectrum beta-lactamase production in nosocomial infections. Ann Intern Med 2004; 140:26-32.
32. McGowan JE Jr. Economic impact of antimicrobial resistance. Emerg Infect Dis 2001; 7:286-92.
33. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003; 36:1433-7.
34. Cosgrove SE, Sakoulas F, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 2003; 36:53-9.
35. Melzer M, Eykyn SJ, Gransden WR, Chinn S. Is methicillin-resistant Staphylococcus aureus more virulent than methicillin-susceptible S. aureus? A comparative cohort study of British patients with nosocomial infection and bacteremia. Clin Infect Dis 2003; 37:1453-60.
36. Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003; 36:592-8.
37. Chaix C, Durand-Zaleski I, Ablerti C, Brun-Buisson C. Control of endemic methicillin-resistant Staphylococcus aureus a cost-benefit analysis in an intensive care unit. JAMA 1999; 282:1745-51.
38. Stosor V, Peterson LR, Postelnick M, Noskin GA. Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998; 158:522-7.
39. DiazGranados CA, Zimmer SM, Klein M, Jernigan JA. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 2005; 41:327-33.
40. Salgado CD, Farr BM. Outcomes associated with vancomycin-resistant enterococci: a meta-analysis. Infect Control Hosp Epidemiol 2003; 24:690-8.
41. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis 2006; 42(Suppl 2):S82-9.
42. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y. Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002; 162:185-90.
43. Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333-41.
44. Institute of Medicine. Antimicrobial drug resistance: issues and options. Workshop report. Washington: National Academy Press, 1998.
45. Ramsay C, Brown E, Hartman G, Davey P. Room for improvement: a systematic review of the quality of evaluations of interventions to improve hospital antibiotic prescribing. J Antimicrob Chemother 2003; 52:764-71.
46. Muto CA, Jernigan JA, Ostrowsky BE, et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol 2003; 24:362-86.
47. Healthcare Infection Control Practices Advisory Committee. Management of multidrug-resistant organisms in healthcare settings, 2006. Available at: http://www.cdc.gov/ncidod/dhqp/index.html.
48. Goldmann DA, Weinstein RA, Wenzel RP, et al. Strategies to prevent and control the emergence and spread of antimicrobial-resistant microorganisms in hospitals: a challenge to hospital leadership. JAMA 1996; 275:234-40.
49. Solomon DH, Van Houten L, Glynn RJ. Academic detailing to improve use of broad-spectrum antibiotics at an academic medical center. Arch Intern Med 2001; 161:1897-902.
50. Fraser GL, Stogsdill P, Dickens JD Jr, Wennberg DE, Smith RP, Prato S. Antibiotic optimization: an evaluation of patient safety and economic outcomes. Arch Intern Med 1997; 157:1689-94.
51. Seligman SJ. Reduction in antibiotic costs by restricting use of an oral cephalosporin. Am J Med 1981; 71:941-4.
52. Britton HL, Schwinghammer TL, Romano MJ. Cost containment through restriction of cephalosporins. Am J Hosp Pharm 1981; 38: 1897-900.
53. Hayman JN, Sbravati EC. Controlling cephalosporin and aminoglycoside costs through pharmacy and therapeutics committee restrictions. Am J Hosp Pharm 1985; 42:1343-7.
54. Woodward RS, Medoff G, Smith MD, Gray JL. Antibiotic cost savings from formulary restrictions and physician monitoring in a medical-school-affiliated hospital. Am J Med 1987; 83:817-23.
55. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O'Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: Experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med 1991; 90:439-44.
56. Maswoswe JJ, Okpara AU. Enforcing a policy for restricting antimicrobial drug use. Am J Health Syst Pharm 1995; 52:1433-5.
57. White AC, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997; 25:230-9.
58. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272-7.
59. Quale J, Landman D, Aurina G, Atwood E, DiTore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23: 1020-5.
60. Bamberger DM, Dahl SL. Impact of voluntary vs. enforced compliance of third-generation cephalosporin use in a teaching hospital. Arch Intern Med 1992; 152:554-7.
61. Anglim AM, Klym B, Byers KE, Scheid WM, Farr BM. Effect of a vancomycin restriction policy on ordering practices during an outbreak of vancomycin-resistant Enterococcus faecium. Arch Intern Med 1997; 157:1132-6.
62. May AK, Melton SM, McGwin G, Cross JM, Moser SA, Rue LW Reduction of vancomycin-resistant enterococcal infections by limitation of broad-spectrum cephalosporin use in a trauma and burn intensive care unit. Shock 2000; 14:259-64.
63. Stiefel U, Paterson DL, Pultz NJ, Gordon SM, Aron DC, Donskey CJ. Effect of the increasing use of piperacillin/tazobactam on the incidence of vancomycin-resistant enterococci in four academic medical centers. Infect Control Hosp Epidemiol 2004; 25:380-3.
64. Lautenbach E, LaRosa LA, Marr AM, Nachamkin I, Bilker WB, Fishman NO. Changes in the prevalence of vancomycin-resistant enterococci in response to antimicrobial formulary interventions: impact of progressive restrictions on use of vancomycin and third-generation cephalosporins. Clin Infect Dis 2003; 36:440-6.
65. de Man P, Verhoeven BAN, Verbrugh HA, Vos MC, van den Anker JN. An antibiotic policy to prevent emergence of resistant bacilli. Lancet 2000; 355:973-8.
66. Toltzis P, Yamashita T, Vilt L, et al. Antibiotic restriction does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit. Crit Care Med 1998; 26:1893-9.
67. DeVito JM, John JF. Effect of formulary restriction of cefotaxime usage. Arch Intern Med 1985; 145:1053-6.
68. Gross R, Morgan AS, Kinky DE, Weiner M, Gibson GA, Fishman NO. Impact of a hospital-based antimicrobial management program on clinical and economic outcomes. Clin Infect Dis 2001; 33:289-95.
69. Burke JP. Antibiotic resistance-squeezing the balloon? JAMA 1998; 280:1270-1.
70. Friedrich LV, White RL, Bosso JA. Impact of use of multiple antimicrobials on changes in susceptibility of gram-negative aerobes. Clin Infect Dis 1999; 28:1017-24.
71. Bantar C, Sartori B, Vesco E, et al. A hospitalwide intervention program to optimize the quality of antibiotic use: impact on prescribing practice, antibiotic consumption, cost savings, and bacterial resistance. Clin Infect Dis 2003; 37:180-6.
72. Belongia EA, Knobloch MJ, Kieke BA, Davis JP, Janette C, Besser RE. Impact of statewide program to promote appropriate antimicrobial drug use. Emerg Infect Dis 2005; 11:912-20.
73. Girotti MJ, Fodoruk S, Irvine-Meek J, Rotstein OD. Antibiotic handbook and pre-printed perioperative order forms for surgical antibiotic prophylaxis: do they work? Can J Surg 1990; 33:383-8.
74. Lomas J, Anderson GM, Domnick-Pierre K, Vayda E, Enkin MW, Hannah WJ. Do practice guidelines guide practice? The effect of a consensus statement of the practice of physicians. N Engl J Med 1989; 321:1306-11.
75. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. JAMA 2000; 283:749-55.
76. Price J, Ekleberry A, Grover A, et al. Evaluation of clinical practice guidelines on outcome of infection in patients in the surgical intensive care unit. Crit Care Med 1999; 27:2118-24.
77. Kollef MH, Sherman G, Ward S, Fraser VJ. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 1999; 115:462-74.
78. Fagon J-Y, Chastre J, Wolff M, et al. Invasive and noninvasive strategies for management of suspected ventilator-associated pneumonia. Ann Intern Med 2000; 132:621-30.
79. Singh N, Rogers P, Atwood CW, Wagener MM, Yu VL. Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. Am J Respir Crit Care Med 2000; 162:505-11.
80. Ibrahim EH, Ward S, Sherman G, Schaiff R, Fraser VJ, Kollef MH. Experience with a clinical guideline for the treatment of ventilator-associated pneumonia. Crit Care Med 2001; 29:1109-15.
81. Chastre J, Wolff M, Fagon J-Y. Comparison of 8 vs. 15 days of antibiotic therapy for ventilator-associated pneumonia in adults. JAMA 2003; 290:2588-98.
82. South M, Starr M. A simple intervention to improve hospital antibiotic prescribing. Med J Aust 2003; 178:207-9.
83. Gerding DN. Antimicrobial cycling: lessons learned from the aminoglycoside experience. Infect Control Hosp Epidemiol 2000; 21(1 Suppl):S12-7.
84. Hodges BM, White RL. Antimicrobial cycling: the future or a fad? Ann Pharmacother 2001; 35:1224-32.
85. Fridkin SK. Routine cycling of antimicrobial agents as an infection-control measure. Clin Infect Dis 2003; 36:1438-44.
86. Dubberke ER, Fraser VJ. Cycling and other strategies to slow and reverse antibiotic resistance. Infect Med 2004; 21:544-56.
87. Moody MM, de Jongh CA, Schimpff SC, Tillman GL. Long-term amikacin use: effects on aminoglycoside susceptibility patterns of gram-negative bacilli. JAMA 1982; 248:1199-202.
88. Betts RF, Valenti WM, Chapman SW, et al. Five-year surveillance of aminoglycoside usage in a university hospital. Ann Intern Med 1984; 100:219-22.
89. Young EJ, Sewell CM, Koza MA, Clarridge JE. Antibiotic resistance patterns during aminoglycoside restriction. Am J Med Sci 1985; 290: 223-7.
90. Berk SL, Alvarez S, Ortega G, Verghese A, Holtsclaw-Berk SA. Clinical and microbiologic consequences of amikacin use during a 42-month period. Arch Intern Med 1986; 146:538-41.
91. Van Landuyt HW, Boelaert J, Gilbert B, Cordts B, Verbruggen A-M. Surveillance of aminoglycoside resistance. Am J Med 1986; 80(Suppl 6B):76-81.
92. Gerding DN, Larson TA, Hughes RA, Weiler M, Shanholtzer C, Peterson LR. Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital. Antimicrob Agents Chemother 1991; 35:1284-90.
93. King JW, White MC, Todd JR, Conrad SA. Alterations in the microbial flora and in the incidence of bacteremia at a university hospital after adoption of amikacin as the sole formulary aminoglycoside. Clin Infect Dis 1992; 14:908-15.
94. Kollef MH, Vlasnik J, Sharpless L, Pasque C, Murphy D, Fraser V. Scheduled change of antibiotic classes: a strategy to decrease the incidence of ventilator-associated pneumonia. Am J Respir Crit Care Med 1997; 156:1040-8.
95. Gruson D, Hilbert G, Vargas F, et al. Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria. Am J Respir Crit Care Med 2000; 162:837-43.
96. Raymond DP, Pelletier SJ, Crabtree TD, et al. Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit. Crit Care Med 2001; 29:1101-8.
97. Bonhoeffer S, Lipsitch M, Levin BR. Evaluating treatment protocols to prevent antibiotic resistance. Proc Natl Acad Sci U S A 1997; 94: 12106-11.
98. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Natl Acad Sci U S A 2004; 7:13101-2.
99. Martinez J-A, Nicolas J-M, Marco F, et al. Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units. Crit Care Med 2006; 34:329-36.
100. Durbin WA, Lapidas B, Goldmann DA. Improved antibiotic usage following introduction of a novel prescription system. JAMA 1981; 246:1796-800.
101. Echols RM, Kowalsky SF. The use of an antibiotic order form for antibiotic utilization review: influence on physicians' prescribing patterns. J Infect Dis 1984; 150:803-7.
102. Classen DC, Evans RS, Pestotnik SL, Horn SD, Menlove RL, Burke JP. The timing of prophylactic administration of antibiotics and the risk of surgical-wound infection. N Engl J Med 1992; 326:281-6.
103. Bratzler DW, Houck PM. Antimicrobial prophylaxis for surgery: an advisory statement from the national surgical infection prevention project. Clin Infect Dis 2004; 38:1706-15.
104. Bolon MK, Arnold AD, Feldman HA, Goldmann DA, Wright SB. An antibiotic order form intervention does not improve or reduce vancomycin use. Pediatr Infect Dis J 2005; 24:1053-8.
105. Hyle EP, Lipworth AD, Zaoutis TE, Nachamkin I, Bilker WB, Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae. Arch Intern Med 2005; 165:1375-80.
106. Harbarth S, Barbino J, Pugin J, Romand JA, Lew D, Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003; 115:529-35.
107. American Thoracic Society and Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 2005; 171:388-416.
108. Bodey GP, Jadeja L, Elting L. Pseudomonas bacteremia: retrospective analysis of 410 episodes. Arch Intern Med 1985; 145:1621-9.
109. Nichols L, Maki DG. The emergence of resistance to beta-lactam antibiotics during treatment of Pseudomonas aeruginosa lower respiratory tract infections: is combination therapy the solution? Chemioterapia 1985; 4:102-9.
110. Milatovic D, Braveny I. Development of resistance during antibiotic therapy. Eur J Clin Microbiol 1987; 6:234-44.
111. Hilf M, Yu VL, Sharp J, Zuravleff JJ, Korvick JA, Muder RR. Antibiotic therapy for Pseudomonas aeruginosa bacteremia: outcome correlations in a prospective study of 200 patients. Am J Med 1989; 87:540-6.
112. Korvick JA, Bryan CS, Farber B, et al. Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy. Antimicrob Agents Chemother 1992; 36:2639-44.
113. Vidal F, Mensa J, Almela M, et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment: analysis of 189 patients. Arch Intern Med 1996; 156:2121-6.
114. Leibovici L, Paul M, Posnanski O, et al. Monotherapy versus beta-lactam-aminoglycoside combination treatment for gram-negative bacteremia: a prospective, observational study. Antimicrob Agents Chemother 1997; 41:1127-33.
115. Chatzinikolaou I, Abi-Said D, Bodey GP, Rolston KV, Tarrand JJ, Samonis G. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501-9.
116. Paul M, Benuri-Silbiger I, Soares-Weiser K, Leibovici L. Beta-lactam monotherapy versus beta-lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomized trials. BMJ 2004; 328:668-81.
117. Safdar N, Handelsman J, Maki DG. Does combination antimicrobial therapy reduce mortality in gram-negative bacteraemia? A meta-analysis. Lancet Infect Dis 2004; 4:519-27.
118. Damas P, Garweg C, Monchi M, et al. Combination therapy versus monotherapy: a randomized pilot study on the evolution of inflammatory parameters after ventilator associated pneumonia. Crit Care 2006; 10:R52.
119. Bliziotis IA, Samonis G, Vardakas KZ, Chrysanthopoulou S, Falagas ME. Effect of aminoglycoside and beta-lactam combination therapy versus β-lactam monotherapy on the emergence of antimicrobial resistance: a meta-analysis of randomized, controlled trials. Clin Infect Dis 2005; 41:149-58.
120. Paterson DL, Rice LB. Empirical antibiotic choice for the seriously ill patient: are minimization of selection of resistant organisms and maximization of individual outcome mutually exclusive? Clin Infect Dis 2003; 36:1006-12.
121. Kollef MH, Kollef KE. Antibiotic utilization and outcomes for patients with clinically suspected ventilator-associated pneumonia and negative quantitative BAL culture results. Chest 2005; 128:2706-13.
122. Briceland LL, Nightingale CH, Quintiliani R, Cooper BW, Smith KS. Antibiotic streamlining from combination therapy to monotherapy utilizing an interdisciplinary approach. Arch Intern Med 1988; 148: 2019-22.
123. Glowacki RC, Schwartz DN, Itokazu GS, Wisniewski MF, Kieszkowski, P, Weinstein RA. Antibiotic combinations with redundant antimicrobial spectra: clinical epidemiology and pilot intervention of computer-assisted surveillance. Clin Infect Dis 2003; 37:59-64.
124. Grant EM, Kuti JL, Nicolau DP, Nightingale C, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous-infusion piperacillin-tazobactam program in a large community teaching hospital. Pharmacotherapy 2002; 22:471-83.
125. Bailey TC, Little JR, Littenberg B, Reichley RM, Dunagan WC. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. Clin Infect Dis 1997; 24:786-95.
126. Saravolatz LD, Legget J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin Infect Dis 2003; 37:1210-5.
127. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60.
128. Chan R, Hemeryck L, O'Regan M, Clancy L, Feely J. Oral versus intravenous antibiotics for community acquired lower respiratory tract infection in a general hospital: open, randomized controlled trial. BMJ 1995; 310:1360-2.
129. Siegel RE, Halpern NA, Almenoff PL, Lee A, Cashin R, Greene JG. A prospective randomized study of inpatient I antibiotics for community-acquired pneumonia. The optimal duration of therapy. Chest 1996; 110:965-71.
130. Omidvari K, de Boisblanc BP, Karam G, Nelson S, Haponik E, Summer W. Early transition to oral antibiotic therapy for community-acquired pneumonia: duration of therapy, clinical outcomes, and cost analysis. Respir Med 1998; 92:1032-9.
131. Al-Eidan FA, McElnay JC, Scott MG, Kearney MP, Troughton KEU, Jenkins J. Sequential antimicrobial therapy: treatment of severe lower respiratory tract infections in children. J Antimicrob Chemother 1999; 44:709-15.
132. Przybylski KG, Rybak MJ, Martin PR, et al. A pharmacist-initiated program of intravenous to oral antibiotic conversion. Pharmacotherapy 1997; 17:271-6.
133. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt) 2003; 4:57-70.
134. McCollum M, Rhew DC, Parodi S. Cost analysis of switching from iv vancomycin to po linezolid for the management of methicillin-resistant Staphylococcus species. Clin Ther 2003; 25:3173-89. 135. Chassin MR, Galvin RW. The urgent need to improve health care quality. Institute of Medicine National Roundtable on Health Care Quality. JAMA 1998; 280:1000-5.
135. Institute of Medicine. Crossing the quality chasm: a new heath system for the 21st century. Washington: National Academy Press, 2000.
136. Institute of Medicine. To err is human: building a safer health system. Washington: National Academy Press, 1999.
137. Kuperman GJ, Gibson RF. Computer physician order entry: benefits, costs, and issues. Ann Intern Med 2003; 139:31-9.
138. Burke JP. Surveillance, reporting, automation, and interventional epidemiology. Infect Control Hosp Epidemiol 2003; 24:10-2.
139. Koppel R, Metlay JP, Cohen A, et al. Role of computerized physician order entry systems in facilitating medication errors. JAMA 2005; 293:1197-203.
140. Burke JP, Classen DC, Pestotnik SL, Evans RS, Stevens LE. The HELP system and its application to infection control. J Hosp Infect 1991; 18(Suppl A):424-31.
141. Evans RS, Pestotnik SL, Classen DC, et al. A computer-assisted management program fro antibiotics and other antiinfective agents. N Engl J Med 1998; 338:232-8.
142. Evans RS, Pestotnik SL, Classen DC, Burke JP. Evaluation of a computer-assisted antibiotic-dose monitor. Ann Pharmacother 1999; 33: 1026-31.
143. Pestotnik SL, Classen DC, Evans RS, Burke JP. Implementing antibiotic practice guidelines through computer-assisted decision support: clinical and financial outcomes. Ann Intern Med 1996; 124:884-90.
144. Burke JP. Maximizing appropriate antibiotic prophylaxis for surgical patients: an update from LDS Hospital, Salt Lake City. Clin Infect Dis 2001; 33(Suppl 2):S78-83.
145. Evans RS, Larsen RA, Burke JP. Computer surveillance of hospital-acquired infections and antibiotic use. JAMA 1986; 256:1007-11.
146. Classen DC, Pestotnik SL, Evans RS, Burke JP. Computerized surveillance of adverse drug events in hospital patients. JAMA 1991; 266: 2847-51.
147. Mullett CJ, Evans RS, Cristenson JC, Dean JM. Development and impact of a computerized pediatric antiinfective decision support system. Pediatrics 2001; 108:e75.
148. Mullett CJ, Thomas JG, Smith CL, Sarwari AR, Khakoo RA. Computerized antimicrobial decision support: an offline evaluation of a database-driven empiric antimicrobial guidance program in hospitalized patients with a bloodstream infection. Int J Med Inform 2004; 73:455-60.
149. Shojania KG, Yokoe D, Platt R, Fiskio J, Ma'luf N, Bates DW. Reducing vancomycin use utilizing a computer guideline: results of a randomized controlled trial. J Am Med Inform Assoc 1998; 5:554-62.
150. Rubinstein E, Barzilai A, Segev S, et al. Antibiotic cost reduction by providing cost information. Eur J Clin Pharmacol 1988; 35:269-72.
151. Wears RL, Berg M. Computer technology and clinical work: still waiting for Godot. JAMA 2005; 293:1261-3.
152. Nebeker JR, Hoffman JM, Weir CR, Bennet CL, Hurdle JF. High rates of adverse drug events in a highly computerized hospital. Arch Intern Med 2005; 165:1111-6.
153. Doern GV, Vautour R, Gaudet M, Levy B. Clinical impact of rapid in vitro susceptibility testing and bacterial identification. J Clin Microbiol 1994; 32:1757-62.
154. Byl B, Clevenbergh P, Jacobs F, et al. Impact of infectious diseases specialists and microbiological data on the appropriateness of antimicrobial therapy for bacteremia. Clin Infect Dis 1999; 29:60-6.
155. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing: fifteenth informational supplement M100-S15, 2005.
156. Clinical and Laboratory Standards Institute (CLSI). Analysis and presentation of cumulative antimicrobial susceptibility test data: approved guideline-second edition. CLSI document M39-A, 2002.
157. Siberry GK, Tekle T, Carroll K, Dick J. Failure of clindamycin treatment of methicillin-resistant Staphylococcus aureus expressing inducible clindamycin resistance in vitro. Clin Infect Dis 2003; 37:1257-60.
158. Roger M, St-Antoine P, Coutlee F. Vancomycin-resistant enterococci in health care facilities. N Engl J Med 2001; 345:768-9.
159. Huletsky A, Lebel P, Picard FJ, et al. Identification of methicillin-resistant Staphylococcus aureus carriage in less than 1 hour during a hospital surveillance program. Clin Infect Dis 2005; 40:976-81.
160. Peterson LR, Noskin GA. New technology for detecting multidrug-resistant pathogens in the clinical microbiology laboratory. Emerg Infect Dis 2001; 7:306-11.
161. Davey P, Brown E, Fenelon L, et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis 2006; 12:211-6.
162. Iokazu GS, Glowacki RC, Schwartz DN, Wisniewski MF, Rydman RJ, Weinstein RA. Antimicrobial consumption data from pharmacy and nursing records: how good are they? Infect Control Hosp Epidemiol 2005; 26:395-400.
163. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32:470-85.
164. Zagorski BM, Trick WE, Schwartz DN, et al. The effect of renal dysfunction on antimicrobial use measurements. Clin Infect Dis 2002; 35:1491-7.
165. Pelletier LL. Hospital usage of parenteral antimicrobial agents: a gradated utilization review and cost containment program. Infect Control 1985; 6:226-30.
166. McGowan JE Jr. Do intensive hospital antibiotic control programs prevent the spread of antibiotic resistance? Infect Control Hosp Epidemiol 1994; 15:478-83.
167. Duncan RA. Controlling use of antimicrobial agents. Infect Control Hosp Epidemiol 1997; 18:260-6.
168. DeLisle S, Perl TM. Antimicrobial management measures to limit resistance: a process-based conceptual framework. Crit Care Med 2001; 29(Suppl):N121-7.
169. Struelens MJ. Multidisciplinary antimicrobial management teams: the way forward to control antimicrobial resistance in hospitals. Curr Opin Infect Dis 2003; 16:305-7.
170. Knox K, Lawson W, Dean B, Holmes A. Multidisciplinary antimicrobial management and the role of the infectious diseases pharmacist-a UK perspective. J Hosp Infect 2003; 53:85-90.
171. Owens RC Jr, Fraser GJ, Stogsdill P. Antimicrobial stewardship programs as a means to optimize antimicrobial use. Pharmacotherapy 2004; 24:896-908.
172. Paskovaty A, Pflomm JM, Myke N, Seo SK. A multidisciplinary approach to antimicrobial stewardship: evolution into the 21st century. Int J Antimicrob Agents 2005; 25:1-10.
173. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Microbiol Rev 2005; 18:638-56.